Luciano Alberto Sposato

Luciano Alberto Sposato

Auto-generated profile, based on publicly available information

Luciano Alberto Sposato

Robarts Research Institute, Department of Clinical Neurological Sciences, and Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada; and

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in The Lancet Neurology
Verified
Journal Article
Closed access
LSLuciano A Sposato
Luciano A Sposato
LCLauren E Cipriano
Lauren E Cipriano
GSGustavo Saposnik
Gustavo Saposnik
EVEstefanía Ruíz Vargas
Estefanía Ruíz Vargas
PRPatricia M Riccio
Patricia M Riccio
VHVladimir Hachinski
Vladimir Hachinski

1 December 2020 in JACC
Verified
Journal Article
Closed access
LSLuciano A. Sposato
Luciano A. Sposato
MHMax J. Hilz
Max J. Hilz
SASara Aspberg
Sara Aspberg
SMSantosh B. Murthy
Santosh B. Murthy
MBM. Cecilia Bahit
M. Cecilia Bahit
JSJan F. Scheitz
Jan F. Scheitz

3 September 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JSJan F. Scheitz
Jan F. Scheitz
LSLuciano A. Sposato
Luciano A. Sposato
JSJeanette Schulz‐Menger
Jeanette Schulz‐Menger
CNChristian H. Nolte
Christian H. Nolte
JBJohannes Backs
Johannes Backs
MEMatthias Endres
Matthias Endres
After ischemic stroke, there is a significant burden of cardiovascular complications, both in the acute and chronic phase. Severe adverse cardiac events occur in 10% to 20% of patients within the first few days after stroke and comprise a continuum of cardiac changes ranging from acute myocardial injury and coronary syndromes to heart failure or arrhythmia. Recently, the term stroke–heart syndrome was introduced to provide an integrated conceptual framework that summarizes neurocardiogenic mechanisms that lead to these cardiac events after stroke. New findings from experimental and clinical studies have further refined our understanding of the clinical manifestations, pathophysiology, and potential long‐term consequences of the stroke–heart syndrome. Local cerebral and systemic mediators, which mainly involve autonomic dysfunction and increased inflammation, may lead to altered cardiomyocyte metabolism, dysregulation of (tissue‐resident) leukocyte populations, and (micro‐) vascular changes. However, at the individual patient level, it remains challenging to differentiate between comorbid cardiovascular conditions and stroke‐induced heart injury. Therefore, further research activities led by joint teams of basic and clinical researchers with backgrounds in both cardiology and neurology are needed to identify the most relevant therapeutic targets that can be tested in clinical trials.

5 March 2025 in EP Europace
Verified
Journal Article
Open access
Wolfram Doehner, MD, PhDWolfram Doehner, MD, PhD
Wolfram Doehner, MD, PhD
Giuseppe BorianiGiuseppe Boriani
Giuseppe Boriani
TPTatajana Potpara
Tatajana Potpara
CBCarina Blomstrom-Lundqvist
Carina Blomstrom-Lundqvist
RPRod Passman
Rod Passman
ACA John Camm
A John Camm
Atrial fibrillation (AF) is one of the most common cardiac diseases and a complicating comorbidity for multiple associated diseases. Many clinical decisions regarding AF are currently based on the binary recognition of AF being present or absent with the categorical appraisal of AF as continued or intermittent. Assessment of AF in clinical trials is largely limited to the time to (first) detection of an AF episode. Substantial evidence shows, however, that the quantitative characteristic of intermittent AF has a relevant impact on symptoms, onset, and progression of AF and AF-related outcomes, including mortality. Atrial fibrillation burden is increasingly recognized as a suitable quantitative measure of intermittent AF that provides an estimate of risk attributable to AF, the efficacy of antiarrhythmic treatment, and the need for oral anticoagulation. However, the diversity of assessment methods and the lack of a consistent definition of AF burden prevent a wider clinical applicability and validation of actionable thresholds of AF burden. To facilitate progress in this field, the AF burden Consensus Group, an international and multidisciplinary collaboration, proposes a unified definition of AF burden. Based on current evidence and using a modified Delphi technique, consensus statements were attained on the four main areas describing AF burden: Defining the characteristics of AF burden, the recording principles, the clinical relevance in major clinical conditions, and implementation as an outcome in the clinic and in clinical trials. According to this consensus, AF burden is defined as the proportion of time spent in AF expressed as a percentage of the recording time, undertaken during a specified monitoring duration. A pivotal requirement for validity and comparability of AF burden assessment is a continuous or near-continuous duration of monitoring that needs to be reported together with the AF burden assessment. This proposed unified definition of AF burden applies independent of comorbidities and outcomes. However, the disease-specific actionable thresholds of AF burden need to be defined according to the targeted clinical outcomes in specific populations. The duration of the longest episode of uninterrupted AF expressed as a time duration should also be reported when appropriate. A unified definition of AF burden will allow for comparability of clinical study data to expand evidence and to establish actionable thresholds of AF burden in various clinical conditions. This proposed definition of AF burden will support risk evaluation and clinical treatment decisions in AF-related disease. It will further promote the development of clinical trials studying the clinical relevance of intermittent AF. A unified approach on AF burden will finally inform the technology development of heart rhythm monitoring towards validated technology to meet clinical needs.

1 March 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
LSLuciano A. Sposato
Luciano A. Sposato
SCSeemant Chaturvedi
Seemant Chaturvedi
CHCheng-Yang Hsieh
Cheng-Yang Hsieh
CMCarlos A. Morillo
Carlos A. Morillo
HKHooman Kamel
Hooman Kamel
Atrial fibrillation (AF) can be newly detected in approximately one-fourth of patients with ischemic stroke and transient ischemic attack without previously recognized AF. We present updated evidence supporting that AF detected after stroke or transient ischemic attack (AFDAS) may be a distinct clinical entity from AF known before stroke occurrence (known atrial fibrillation). Data suggest that AFDAS can arise from the interplay of cardiogenic and neurogenic forces. The embolic risk of AFDAS can be understood as a gradient defined by the prevalence of vascular comorbidities, the burden of AF, neurogenic autonomic changes, and the severity of atrial cardiopathy. The balance of existing data indicates that AFDAS has a lower prevalence of cardiovascular comorbidities, a lower degree of cardiac abnormalities than known atrial fibrillation, a high proportion (52%) of very brief (<30 seconds) AF paroxysms, and is more frequently associated with insular brain infarction. These distinctive features of AFDAS may explain its recently observed lower associated risk of stroke than known atrial fibrillation. We present an updated ad-hoc meta-analysis of randomized clinical trials in which the association between prolonged cardiac monitoring and reduced risk of ischemic stroke was nonsignificant (incidence rate ratio, 0.90 [95% CI, 0.71–1.15]). These findings highlight that larger and sufficiently powered randomized controlled trials of prolonged cardiac monitoring assessing the risk of stroke recurrence are needed. Meanwhile, we call for further research on AFDAS and stroke recurrence, and a tailored approach when using prolonged cardiac monitoring after ischemic stroke or transient ischemic attack, focusing on patients at higher risk of AFDAS and, more importantly, at higher risk of cardiac embolism.

1 January 2024 in Stroke
Verified
Journal Article
Closed access
LSLuciano A Sposato
Luciano A Sposato
CACatherine S W Albin
Catherine S W Albin
MEMitchell Elkind
Mitchell Elkind
HKHooman Kamel
Hooman Kamel
JSJeffrey L Saver
Jeffrey L Saver
Patent foramen ovale (PFO) is frequently identified in young patients with ischemic stroke. Randomized controlled trials provide robust evidence supporting PFO closure in selected patients with cryptogenic ischemic stroke; however, several questions remain unanswered. This report summarizes current knowledge on the epidemiology of PFO-associated stroke, the role of PFO as a cause of stroke, and anatomic high-risk features. We also comment on breakthrough developments in patient selection algorithms for PFO closure in relation to the PFO-associated stroke causal likelihood risk stratification system. We further highlight areas for future research in PFO-associated stroke including the efficacy and safety of PFO closure in the elderly population, incidence, and long-term consequences of atrial fibrillation post-PFO closure, generalizability of the results of clinical trials in the real world, and the need for assessing the effect of neurocardiology teams on adherence to international recommendations. Other important knowledge gaps such as sex, race/ethnicity, and regional disparities in access to diagnostic technologies, PFO closure devices, and clinical outcomes in the real world are also discussed as priority research topics.